Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048945 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 820
- Enrollment target
NCT00048945 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 820 participants.
The verdict
NCT00048945, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 820 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Interventions
- DRUG PEGASYS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 820 participants |
| Start Date | 2002-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048945
The ClinicalTrials.gov registry entry for NCT00048945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 820 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEGASYS is the first listed.
NCT00048945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048945 about?
NCT00048945 is a clinical study titled "Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B". The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
What is the current status of trial NCT00048945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 820 participants. The study started on 2002-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00048945?
The interventions under investigation include: PEGASYS (DRUG).
Who is sponsoring clinical trial NCT00048945?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.